KRAS and neoplasm: Overall, 40.5% of patients with available primary tumor tissue had a BRAF mutation in their tumor tissue (35.1% BRAFV600E, 2.7% BRAFV600R, BRAFV600K 2.7%), 18.9% of patients had a NRAS mutation (10.8% NRASQ61R, 8.1% NRASQ61K) and one patient (2.9%) had a KRAS mutation (KRASG12) in their tissue.